
Odontogenic infection is the most common cause of fascial space abscesses in the head and neck region1. These abscesses mainly originate from pulpitis, periodontitis, or pericoronitis. Pulpitis with dental caries is the most frequent, followed by pericoronitis and periodontitis2. A well-localized abscess can be treated by eliminating the origin of the infection with incision and drainage. However, in cases of severe infection or compromised immunity, antibiotic therapy is required, and if not treated appropriately, lethal complications such as airway obstruction, necrotizing fasciitis, sepsis, and mediastinitis can occur3.
Odontogenic fascial space abscesses are polymicrobial infections consisting of various aerobic, facultative anaerobic, and obligate anaerobic bacteria. The causative bacteria are mostly part of the normal flora in the oral cavity of the host4-6.
In the treatment of fascial space abscesses, it is essential to test bacterial cultures to accurately identify the causative strains of infection and select a narrow range of antibiotics depending on the antibiotic sensitivity of the strain. Since these bacterial culture and antibiotic sensitivity tests take several days, empirical antibiotics should be used in the initial stage. The frequently used empirical antibiotics include penicillin, cephalosporin, and clindamycin. Because of the predominance of Gram-positive aerobic strains in odontogenic infections, beta-lactam antibiotics are mainly selected as empirical antibiotics for initial treatment9.
For prophylaxis and the treatment of infections, dentists mostly prescribe broad-spectrum antibiotics. Even when sufficient treatment is possible through the elimination of the infection source, antibiotics are often also prescribed10, which causes unnecessary exposure to a wide range of antibiotics as they are prescribed without bacterial culture and antibiotic sensitivity tests11,12. Accordingly, several studies reported that antibiotic resistance among causative strains of odontogenic infections has been increasing13,14.
This study aimed to identify bacterial isolates and their antibiotic sensitivity in patients who were hospitalized for odontogenic fascial space abscesses between 2013 and 2022. Moreover, temporal changes over the past 10 years were identified to provide a reference for selecting the appropriate empirical antibiotics before receiving the results of bacterial culture tests.
This study included patients who were admitted to the Department of Oral and Maxillofacial Surgery, Dankook University Hospital between 2013 and 2022 for fascial space abscesses with odontogenic infection. Patients who underwent pus culture tests and antibiotic sensitivity tests following incision and drainage were included in this study. Patients with negative results and contaminated samples were excluded. If more than three different species were detected in the sample, the specimen was considered contaminated, and further culture tests were not conducted by our hospital’s Department of Diagnostic Laboratory Medicine. In cases of mild abscesses in which no considerable amount of pus was accumulated or sampled due to preoperative antibiotic administration, the growth of bacteria may not be detected in the culture. Specimens were collected by the ‘swabbing method’ using a sterile culture swab in an aseptic surgical environment. The number of patients whose samples underwent culturing via the aspiration method in our clinic was small. Thus, to obtain sufficient data obtained under the same conditions for a period of 10 years, the swabbing method was chosen. A fascial space abscess was diagnosed through clinical and radiographic examinations, and the patient’s dental history, panoramic view, periapical view, and enhanced computed tomography (CT) images were evaluated to confirm the dental origin of the infection.
To investigate changes in bacterial isolates and antibiotic sensitivity over the study period, the patients were divided into two groups based on their hospital visit dates: patients treated between 2013 and 2017 and those treated between 2018 and 2022. The identified strains and their antibiotic sensitivities were compared and analyzed between the groups, representing the past 5 years and the recent 5 years.
Fascial space with abscess formation was confirmed through enhanced CT imaging and classified into primary, secondary, and deep neck fascial space. Primary fascial spaces are spaces directly affected by odontogenic infection adjacent to the tooth apex or periodontal tissues, including canine, buccal, submental, sublingual, submandibular, and infratemporal spaces. Secondary fascial spaces, into which bacteria can spread from primary spaces, are located between masticatory muscles or in the loose connective tissue adjacent to the masticatory muscles. Finally, deep neck spaces, which include the lateral pharyngeal space and the retropharyngeal space, are spaces where infection can spread beyond the secondary spaces and cause complications such as upper airway obstruction or mediastinitis. We analyzed the differences in identified strains and their percentages among groups classified according to fascial space abscesses.
For statistical analysis, IBM SPSS Statistics (ver. 28; IBM) was used, and
This study was approved by the Institutional Review Board (IRB) of the Dankook University Dental Hospital (DKUDH IRB 2023-03-007). Because of the retrospective nature of the study, which did not use identifying personal information, the IRB waived the need to obtain written informed consent from the study participants.
A total of 192 patients were included in this study from 2013 to 2022 and divided into two groups based on visit dates. In the patients treated between 2013-2017, the 79 patients comprised 40 males (50.6%) and 39 females (49.4%), whereas in the group treated 2018-2022, the 113 patients comprised 68 males (60.2%) and 45 females (39.8%). The sex distribution was not significantly different between the two groups. In the 2013-2017 group, the mean age of the male and female patients was 49.7 and 65.5 years, respectively, whereas in the 2018-2022 group, the mean age of male and female patients was 53.2 and 65.2 years, respectively, with no significant difference between the two groups.(Table 1) In the overall patient group, the most frequently affected fascial space was the submandibular space (22.7%), followed by the submasseteric space (14.7%), the pterygomandibular space (13.1%), the buccal space (9.1%), and the sublingual space (8.9%). There was no significant difference in involved fascial spaces between the two groups.(Table 2) Among the 192 patients, 65 patients (33.9%) had a single-space involvement, and 127 patients (66.1%) had more than two spaces involved.
A total of 302 strains were detected in pus cultures from the 192 patients, with a mean of 1.57 strains per patient.(Table 3) Aerobic strains comprised 73.8% of the 302 strains and anaerobic strains comprised 26.2%. Most strains (73.2%) were Gram-positive bacteria were 73.2%, while 26.8% were Gram-negative bacteria. The most frequently identified bacterial isolate was viridans streptococcus (51.7%), followed by
In the comparison of bacteria in the 2013-2017 and 2018-2022 groups (Tables 3, 4), the frequency of Gram-positive aerobic bacteria significantly increased from 56.8% to 72.4%, whereas the frequency of Gram-negative anaerobic bacteria significantly decreased from 23.3% to 12.8%. Among the Gram-positive aerobic bacteria, the prevalence of viridans streptococci significantly increased from 41.8% to 60.9%; among the Gram-negative anaerobes, the prevalence of
We next compared whether there was a difference in bacterial isolates in patients with primary, secondary, and deep neck space abscesses.(Tables 5, 6) The percentage of Gram-positive aerobic bacteria was significantly lower and the percentage of Gram-negative aerobic bacteria was significantly higher in patients with deep neck space abscesses than in those with primary or secondary space abscesses. In particular, viridans streptococci had a lower percentage, and
Table 7 shows the antibiotic sensitivity results of viridans streptococcus. Antibiotic sensitivity to penicillin G and ampicillin was 60.4% and 80.5%, respectively, and 93.5% and 95.5% to cefotaxime and ceftriaxone (third-generation cephalosporin drugs), respectively. Antibiotic resistance to erythromycin and clindamycin was 31.2% and 27.6%, respectively. The tested strains were 100.0%, 96.1%, and 99.4% sensitive to linezolid, levofloxacin, and vancomycin, respectively. In the analysis of response to tetracycline, 44.2% showed antibiotic sensitivity and 47.4% showed antibiotic resistance. The antibiotic sensitivity to penicillin G significantly decreased from 68.4% in 2013-2017 to 52.0% in 2018-2022. No significant differences for other antibiotics were found.(Table 8)
Table 9 shows the antibiotic sensitivity results for
The causes of odontogenic fascial space abscesses include periapical disease, periodontal disease, and pericoronitis. In the study by Dahlén15, the
In this study, viridans streptococci showed a sensitivity of 60.4% and 80.5% to penicillin G and ampicillin, respectively, and approximately 94% to the third-generation cephalosporin. The strains showed a decreasing trend in sensitivity to penicillin G and ampicillin over the past 10 years but maintained an antibiotic sensitivity of 95% to cefotaxime and ceftriaxone, which are third-generation cephalosporins. Hirai et al.16 reported that strains of the
In a study on deep neck abscesses conducted by Lee and Kanagalingam22 in 2011,
In the present study, the percentage of
This study has several limitations. In this study, patients with head and neck fascial space abscesses due to odontogenic infections treated over the past 10 years were included, but patients who did not undergo appropriate bacterial culture and antibiotic sensitivity tests were excluded from the study; therefore, the sample of the target population was insufficient. Unlike strains with a high identification rate,
Viridans streptococcus was the most frequently detected strain in pus cultures from patients hospitalized for odontogenic fascial space abscesses. The frequency of viridans streptococcus increased in the last 10 years. Empirical antibiotics should comprise drugs with expected activity against viridans streptococcus. Viridans streptococcus showed an antibiotic sensitivity of 80.5% to ampicillin, but the sensitivity to penicillin antibiotics has been decreasing for the last 10 years. For third-generation cephalosporins such as cefotaxime or ceftriaxone, approximately 94% of sensitivity has been maintained over the past 10 years. In patients with deep neck space abscesses, viridans streptococcus accounted for the frequency, but the percentage of Gram-negative aerobic strains including
G.B.K. participated in data collection, performed the statistical analysis and wrote the manuscript. C.H.K. participated in the study design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
This study was approved by the IRB of the Dankook University Dental Hospital (DKUDH IRB 2023-03-007). Because of the retrospective nature of the study, which did not use identifying personal information, the IRB waived the need to obtain written informed consent from the study participants.
No potential conflict of interest relevant to this article was reported.
Demographic information of the patients in the two study periods
2013-2017 | 2018-2022 | |||||||
---|---|---|---|---|---|---|---|---|
Total | Male | Female | Total | Male | Female | |||
No. of patients | 79 (100.0) | 40 (50.6) | 39 (49.4) | 113 (100.0) | 68 (60.2) | 45 (39.8) | 0.217 | |
Mean age (yr) | 57.5 | 49.7 | 65.5 | 58.0 | 53.2 | 65.2 | 0.207 (male), 0.924 (female) |
Values are presented as number (%) or mean only.
Comparison of the distribution of the spaces involved in odontogenic infections in the study periods 2013-2017 and 2018-2022
Total | 2013-2017 | 2018-2022 | ||
---|---|---|---|---|
Primary fascial space | ||||
Submandibular space | 22.7 | 27.4 | 19.9 | 0.095 |
Buccal space | 9.1 | 9.6 | 8.9 | 0.117 |
Sublingual space | 8.9 | 5.7 | 10.7 | 0.084 |
Submental space | 8.4 | 8.9 | 8.1 | 0.719 |
Infratemproal space | 6.1 | 6.4 | 5.9 | >0.999 |
Canine space | 1.6 | 1.9 | 1.5 | 0.391 |
Dentoalveolar space | 1.4 | 1.9 | 1.1 | 0.391 |
Secondary fascial space | ||||
Submasseteric space | 14.7 | 14.0 | 15.1 | 0.778 |
Pterygomandibular space | 13.1 | 11.5 | 14.0 | 0.373 |
Superficial & deep temporal space | 5.6 | 5.1 | 5.9 | 0.030 |
Deep neck space | ||||
Lateral pharyngeal space | 6.5 | 5.7 | 7.0 | 0.012 |
Retropharyngeal space | 1.9 | 1.9 | 1.8 | >0.999 |
Values are presented as % only.
Microbiology results and temporal changes in bacterial isolates of patients with odontogenic infections
Total | Year | ||||
---|---|---|---|---|---|
2013-2017 | 2018-2022 | ||||
n | % | % | % | ||
Gram (+) | |||||
Aerobes | |||||
17 | 5.6 | 6.2 | 5.1 | ||
1 | 0.3 | 0.0 | 0.6 | ||
1 | 0.3 | 0.0 | 0.6 | ||
2 | 0.7 | 0.7 | 0.6 | ||
Group D streptococcus | 8 | 2.6 | 3.4 | 1.9 | |
Viridans streptococcus | 156 | 51.7 | 41.8 | 60.9 | |
β-hemolytic streptococcus | 2 | 0.7 | 0.7 | 0.6 | |
4 | 1.3 | 2.7 | 0.0 | ||
Other Gram (+) aerobic cocci | 1 | 0.3 | 0.7 | 0.0 | |
4 | 1.3 | 0.7 | 1.9 | ||
Anaerobes | |||||
14 | 4.6 | 6.8 | 2.6 | ||
4 | 1.3 | 0.0 | 2.6 | ||
Other Gram (+) anaerobic cocci | 4 | 1.3 | 2.7 | 0.0 | |
Other Gram (+) anaerobic rods | 3 | 1.0 | 0.7 | 1.3 | |
Gram (–) | |||||
Aerobes | |||||
14 | 4.6 | 3.4 | 5.8 | ||
6 | 2.0 | 2.1 | 1.9 | ||
1 | 0.3 | 0.0 | 0.6 | ||
5 | 1.7 | 3.4 | 0.0 | ||
1 | 0.3 | 0.7 | 0.0 | ||
Anaerobes | |||||
51 | 16.9 | 22.6 | 11.5 | ||
1 | 0.3 | 0.0 | 0.6 | ||
1 | 0.3 | 0.7 | 0.0 | ||
1 | 0.3 | 0.0 | 0.6 |
Comparison of bacterial isolates in odontogenic infections between 2013-2017 and 2018-2022
2013-2017 | 2018-2022 | |||||
---|---|---|---|---|---|---|
n | % | n | % | |||
Gram (+) aerobes | 83 | 56.8 | 113 | 72.4 | 0.007* | |
Gram (+) anaerobes | 15 | 10.3 | 10 | 6.4 | 0.199 | |
Gram (–) aerobes | 14 | 9.6 | 13 | 8.3 | 0.549 | |
Gram (–) anaerobes | 34 | 23.3 | 20 | 12.8 | 0.024* | |
Total | 146 | 100 | 156 | 100 |
*
Bacterial isolates from samples of patients with odontogenic infections according to involved fascial spaces
Head & neck fascial space | ||||||||
---|---|---|---|---|---|---|---|---|
Primary | Secondary | Deep neck | ||||||
n | % | n | % | n | % | |||
Gram (+) | ||||||||
Aerobes | ||||||||
7 | 5.4 | 7 | 6.5 | 3 | 4.6 | |||
0 | 0.0 | 0 | 0.0 | 1 | 1.5 | |||
1 | 0.8 | 0 | 0.0 | 0 | 0.0 | |||
2 | 1.6 | 0 | 0.0 | 0 | 0.0 | |||
Group D streptococcus | 3 | 2.3 | 4 | 3.7 | 1 | 1.5 | ||
Viridans streptococcus | 74 | 57.4 | 56 | 51.9 | 26 | 40.0 | ||
β-hemolytic streptococcus | 1 | 0.8 | 1 | 0.9 | 0 | 0.0 | ||
1 | 0.8 | 3 | 2.8 | 0 | 0.0 | |||
Other Gram (+) aerobic cocci | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | ||
2 | 1.6 | 1 | 0.9 | 1 | 1.5 | |||
Anaerobes | ||||||||
5 | 3.9 | 5 | 4.6 | 4 | 6.2 | |||
2 | 1.6 | 2 | 1.9 | 0 | 0.0 | |||
Other Gram (+) anaerobic cocci | 1 | 0.8 | 2 | 1.9 | 1 | 1.5 | ||
Other Gram (+) anaerobic rods | 1 | 0.8 | 1 | 0.9 | 1 | 1.5 | ||
Gram (–) | ||||||||
Aerobes | ||||||||
4 | 3.1 | 3 | 2.8 | 7 | 10.8 | |||
0 | 0.0 | 1 | 0.9 | 5 | 7.7 | |||
0 | 0.0 | 1 | 0.9 | 0 | 0.0 | |||
3 | 2.3 | 1 | 0.9 | 1 | 1.5 | |||
0 | 0.0 | 0 | 0.0 | 1 | 1.5 | |||
Anaerobes | ||||||||
21 | 16.3 | 18 | 16.7 | 12 | 18.5 | |||
0 | 0.0 | 1 | 0.9 | 0 | 0.0 | |||
1 | 0.8 | 0 | 0.0 | 0 | 0.0 | |||
0 | 0.0 | 0 | 0.0 | 1 | 1.5 |
Comparison of bacterial isolates according to fascial spaces
n | % | n | % | |||
---|---|---|---|---|---|---|
Primary space (n=129) | Secondary space (n=108) | |||||
Gram (+) aerobes | 91 | 70.5 | 73 | 67.6 | 0.868 | |
Gram (+) anaerobes | 9 | 7.0 | 10 | 9.3 | 0.760 | |
Gram (–) aerobes | 7 | 5.4 | 6 | 5.6 | 0.739 | |
Gram (–) anaerobes | 22 | 17.1 | 19 | 17.6 | 0.842 | |
Primary space (n=129) | Deep neck space (n=65) | |||||
Gram (+) aerobes | 91 | 70.5 | 32 | 49.2 | 0.003* | |
Gram (+) anaerobes | 9 | 7.0 | 6 | 9.2 | 0.622 | |
Gram (–) aerobes | 7 | 5.4 | 14 | 21.5 | <0.001* | |
Gram (–) anaerobes | 22 | 17.1 | 13 | 20.0 | 0.609 | |
Secondary space (n=108) | Deep neck space (n=65) | |||||
Gram (+) aerobes | 73 | 67.6 | 32 | 49.2 | 0.006* | |
Gram (+) anaerobes | 10 | 9.3 | 6 | 9.2 | 0.463 | |
Gram (–) aerobes | 6 | 5.6 | 14 | 21.5 | 0.002* | |
Gram (–) anaerobes | 19 | 17.6 | 13 | 20.0 | 0.747 |
*
Antibiotic sensitivity of viridans streptococcus in 2013-2022
No. of strains | % | |
---|---|---|
Penicillin G | ||
R | 6 | 3.9 |
I | 55 | 35.7 |
S | 93 | 60.4 |
Ampicillin | ||
R | 7 | 4.5 |
I | 23 | 14.9 |
S | 124 | 80.5 |
Cefotaxime | ||
R | 7 | 4.5 |
I | 3 | 1.9 |
S | 144 | 93.5 |
Ceftriaxone | ||
R | 6 | 3.9 |
I | 1 | 0.6 |
S | 147 | 95.5 |
Levofloxacin | ||
R | 4 | 2.6 |
I | 2 | 1.3 |
S | 148 | 96.1 |
Erythromycin | ||
R | 48 | 31.2 |
I | 1 | 0.6 |
S | 105 | 68.2 |
Clindamycin | ||
R | 41 | 27.6 |
I | 4 | 2.6 |
S | 109 | 70.8 |
Linezolid | ||
R | 0 | 0.0 |
I | 0 | 0.0 |
S | 154 | 100.0 |
Vancomycin | ||
R | 1 | 0.6 |
I | 0 | 0.0 |
S | 153 | 99.4 |
Tetracycline | ||
R | 73 | 47.4 |
I | 13 | 8.4 |
S | 68 | 44.2 |
(R: resistant, I: intermediate, S: sensitive)
Comparison of antibiotic sensitivity of viridans streptococcus between 2013-2017 and 2018-2022
2013-2017 | 2018-2022 | |||||
---|---|---|---|---|---|---|
No. of strains | % | No. of strains | % | |||
Penicillin G | ||||||
R | 3 | 3.8 | 3 | 4.0 | >0.999 | |
I | 22 | 27.8 | 33 | 44.0 | 0.039* | |
S | 54 | 68.4 | 39 | 52.0 | 0.043* | |
Ampicillin | ||||||
R | 4 | 5.1 | 3 | 4.0 | 0.766 | |
I | 9 | 11.4 | 14 | 18.7 | 0.165 | |
S | 66 | 83.5 | 58 | 77.3 | 0.274 | |
Cefotaxime | ||||||
R | 4 | 5.1 | 3 | 4.0 | 0.766 | |
I | 2 | 2.5 | 1 | 1.3 | 0.380 | |
S | 73 | 92.4 | 71 | 94.7 | 0.453 | |
Ceftriaxone | ||||||
R | 3 | 3.8 | 3 | 4.0 | >0.999 | |
I | 0 | 0.0 | 1 | 1.3 | 0.375 | |
S | 76 | 96.2 | 71 | 94.7 | 0.765 | |
Levofloxacin | ||||||
R | 4 | 5.1 | 0 | 0.0 | 0.051 | |
I | 1 | 1.3 | 1 | 1.3 | >0.999 | |
S | 74 | 93.7 | 74 | 98.7 | 0.096 | |
Erythromycin | ||||||
R | 25 | 31.6 | 23 | 30.7 | 0.894 | |
I | 0 | 0.0 | 1 | 1.3 | 0.375 | |
S | 54 | 68.4 | 51 | 68.0 | >0.999 | |
Clindamycin | ||||||
R | 23 | 29.1 | 18 | 24.0 | 0.484 | |
I | 2 | 2.5 | 2 | 2.7 | >0.999 | |
S | 54 | 68.4 | 55 | 73.3 | 0.498 | |
Linezolid | ||||||
R | 0 | 0.0 | 0 | 0.0 | >0.999 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 79 | 100.0 | 75 | 100.0 | >0.999 | |
Vancomycin | ||||||
R | 1 | 1.3 | 0 | 0.0 | 0.387 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 78 | 98.7 | 75 | 100.0 | 0.387 | |
Tetracycline | ||||||
R | 37 | 46.8 | 36 | 48.0 | 0.902 | |
I | 6 | 7.6 | 7 | 9.3 | 0.824 | |
S | 36 | 45.6 | 32 | 42.7 | 0.709 |
(R: resistant, I: intermediate, S: sensitive)
*
Antibiotic sensitivity of
No. of strains | % | |
---|---|---|
Ampicillin | ||
R | 18 | 100.0 |
I | 0 | 0.0 |
S | 0 | 0.0 |
Amoxicillin/CA | ||
R | 1 | 5.6 |
I | 2 | 11.1 |
S | 15 | 83.3 |
Pip/tazobactam | ||
R | 0 | 0.0 |
I | 2 | 11.1 |
S | 16 | 88.9 |
Cefazolin | ||
R | 4 | 22.2 |
I | 0 | 0.0 |
S | 14 | 77.8 |
Cefoxitin | ||
R | 1 | 5.6 |
I | 0 | 0.0 |
S | 17 | 94.4 |
Cefotaxime | ||
R | 3 | 16.7 |
I | 1 | 5.6 |
S | 14 | 77.8 |
Ceftazidime | ||
R | 4 | 22.2 |
I | 0 | 0.0 |
S | 14 | 77.8 |
Cefepime | ||
R | 1 | 5.6 |
I | 0 | 0.0 |
S | 17 | 94.4 |
Aztreonam | ||
R | 2 | 11.1 |
I | 0 | 0.0 |
S | 16 | 88.9 |
Ertapenem | ||
R | 0 | 0.0 |
I | 0 | 0.0 |
S | 18 | 100.0 |
Imipenem | ||
R | 0 | 0.0 |
I | 0 | 0.0 |
S | 18 | 100.0 |
Amikacin | ||
R | 1 | 5.6 |
I | 0 | 0.0 |
S | 17 | 94.4 |
Gentamicin | ||
R | 4 | 22.2 |
I | 0 | 0.0 |
S | 14 | 77.8 |
Ciprofloxacin | ||
R | 2 | 11.1 |
I | 0 | 0.0 |
S | 16 | 88.9 |
Tigecycline | ||
R | 0 | 0.0 |
I | 1 | 5.6 |
S | 17 | 94.4 |
Trimethoprim/sulfa | ||
R | 1 | 5.6 |
I | 0 | 0.0 |
S | 17 | 94.4 |
(R: resistant, I: intermediate, S: sensitive, CA: clavulanic acid, Pip: piperacillin)
Comparison of antibiotic sensitivity of
2013-2017 | 2018-2022 | |||||
---|---|---|---|---|---|---|
No. of strains | % | No. of strains | % | |||
Ampicillin | ||||||
R | 6 | 100.0 | 12 | 100.0 | >0.999 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 0 | 0.0 | 0 | 0.0 | >0.999 | |
Amoxicillin/CA | ||||||
R | 0 | 0.0 | 1 | 8.3 | 0.489 | |
I | 0 | 0.0 | 2 | 16.7 | 0.297 | |
S | 6 | 100.0 | 9 | 75.0 | 0.192 | |
Pip/tazobactam | ||||||
R | 0 | 0.0 | 0 | 0.0 | >0.999 | |
I | 0 | 0.0 | 2 | 16.7 | 0.297 | |
S | 6 | 100.0 | 10 | 83.3 | 0.297 | |
Cefazolin | ||||||
R | 0 | 0.0 | 4 | 33.3 | 0.122 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 8 | 66.7 | 0.122 | |
Cefoxitin | ||||||
R | 0 | 0.0 | 1 | 8.3 | 0.489 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 11 | 91.7 | 0.489 | |
Cefotaxime | ||||||
R | 0 | 0.0 | 3 | 25.0 | 0.192 | |
I | 0 | 0.0 | 1 | 8.3 | 0.489 | |
S | 6 | 100.0 | 8 | 66.7 | 0.122 | |
Ceftazidime | ||||||
R | 0 | 0.0 | 4 | 33.3 | 0.122 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 8 | 66.7 | 0.122 | |
Cefepime | ||||||
R | 0 | 0.0 | 1 | 8.3 | 0.489 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 11 | 91.7 | 0.489 | |
Aztreonam | ||||||
R | 0 | 0.0 | 2 | 16.7 | 0.297 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 10 | 83.3 | 0.297 | |
Ertapenem | ||||||
R | 0 | 0.0 | 0 | 0.0 | >0.999 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 12 | 100.0 | >0.999 | |
Imipenem | ||||||
R | 0 | 0.0 | 0 | 0.0 | >0.999 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 12 | 100.0 | >0.999 | |
Amikacin | ||||||
R | 0 | 0.0 | 1 | 8.3 | 0.489 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 11 | 91.7 | 0.489 | |
Gentamicin | ||||||
R | 0 | 0.0 | 4 | 33.3 | 0.122 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 8 | 66.7 | 0.122 | |
Ciprofloxacin | ||||||
R | 0 | 0.0 | 2 | 16.7 | 0.297 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 10 | 83.3 | 0.297 | |
Tigecycline | ||||||
R | 0 | 0.0 | 0 | 0.0 | >0.999 | |
I | 0 | 0.0 | 1 | 8.3 | 0.489 | |
S | 6 | 100.0 | 11 | 91.7 | 0.489 | |
Trimethoprim/sulfa | ||||||
R | 0 | 0.0 | 1 | 8.3 | 0.489 | |
I | 0 | 0.0 | 0 | 0.0 | >0.999 | |
S | 6 | 100.0 | 11 | 91.7 | 0.489 |
(R: resistant, I: intermediate, S: sensitive, CA: clavulanic acid, Pip: piperacillin)